Tumor Necrosis Factor-Induced Neuropilin-2 in Fibroblast-Like Synoviocytes Exacerbates Rheumatoid Arthritis.

Abstract

We investigated tumor necrosis factor (TNF)-induced neuropilin-2 (NRP2) in rheumatoid arthritis (RA) and focused on its role in inflammation and disease progression and its potential as a therapeutic target in fibroblast-like synoviocytes (FLS). Serum and synovial fluid (SF) samples were collected from healthy volunteers (serum, n = 30), patients with osteoarthritis (OA) (SF, n = 20), and patients with RA (serum, n = 76; SF, n = 21) for NRP2 quantification. Synovial tissues from patients with OA (n = 6) and RA (n = 6) were obtained to analyze NRP2 expression and its clinical relevance. Systemic or conditional NRP2 knockout mice were generated, and disease severity was evaluated in serum-transfer-induced arthritis (STIA) models. RA-FLS were transfected with NRP2-specific small interfering RNA to assess the effects on proliferation, apoptosis, and pro-inflammatory cytokine secretion. Chromatin immunoprecipitation sequencing (ChIP-seq) was performed to identify p65-binding sites in the NRP2 locus. NRP2 levels in RA serum (n = 76) were elevated and correlated with disease activity. TNF up-regulated NRP2 expression in FLS via the transcription factor p65, and elevated NRP2 in turn, amplified local inflammation and tissue damage by increasing FLS proliferation and promoting the release of cytokines, chemokines, and matrix metalloproteinases (MMPs). Both systemic and conditional knockout of NRP2 alleviated joint inflammation and damage in STIA models. The inflammatory regulation mediated by NRP2 was derived primarily from α⁺THY1⁺ subset within the synovial sublining layer. TNF-induced NRP2 drives inflammatory persistence in RA and serves as a promising diagnostic biomarker. Targeting the TNF-p65-NRP2 axis in FLS may offer a novel strategy for mitigating arthritis progression.